DRES-08. A NOVEL XENOGRAFT MODEL REVEALS A GENE CASCADE AND SERUM BIOMARKER DEFINING A MESENCHYMAL TRANSITION DURING THE EVOLUTION OF GLIOBLASTOMA RESISTANCE TO ANTI-ANGIOGENIC THERAPY

INTRODUCTION: Bevacizumab treatment of glioblastoma is limited by transient response and acquired resistance. To study transcriptional changes underlying the evolution of bevacizumab resistance and identify resistance biomarkers, we created a novel multigenerational xenograft model of acquired bevac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Jahangiri, Arman, Chen, William, Nguyen, Alan, Rick, Jonathan, Kuang, Ruby, Sidorov, Maxim, Flanigan, Patrick M, Wagner, Jeffrey R, Carbonell, W Shawn, Yagnik, Garima, Aghi, Manish K
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691977/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.266
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars